Joaquin Duato, J&J CEO (Amir Hamja/Bloomberg via Getty Images)

J&J re­it­er­ates 2025 sales goal de­spite loom­ing Ste­lara ex­clu­siv­i­ty loss, glob­al eco­nom­ic chal­lenges

John­son & John­son is dou­bling down on a mid-decade phar­ma sales goal, and it’s plot­ting a way even as it los­es ex­clu­siv­i­ty on one of its main block­busters lat­er this year.

Joaquin Du­a­to — who be­came J&J’s CEO last year af­ter Alex Gorsky stepped aside — re­peat­ed the com­pa­ny’s tar­get for $60 bil­lion in phar­ma sales rev­enue by 2025 in an in­vestor call Tues­day morn­ing.

That fig­ure was laid out as a rev­enue goal for 2025 last year, when ex­ecs said on the Q3 earn­ings call that the tar­get num­ber was still pos­si­ble through what J&J had in sales and in its pipeline at the time.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.